For the year ending 2025-12-31, VXRT had $28,585K increase in cash & cash equivalents over the period. $7,569K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Revenues | 237,258 |
| Research and development expense-Norovirus Program | 3,638 |
| Research and development expense-Covid19Program | 155,049 |
| Research and development expense-Other Programs | 345 |
| Research and development expense-Preclinical Research | 767 |
| Research and development expense-Process Development Program | 46 |
| Research and development expense-Internal Research And Development Costs | 41,731 |
| General and administrative | 17,608 |
| Interest income | 1,596 |
| Non-cash interest expense related to sale of future royalties | 2,823 |
| Other segment items | 44 |
| Income tax expense (benefit) | 476 |
| Net income (loss) | 16,327 |
| Depreciation and amortization | 8,579 |
| Loss on disposal of property and equipment | -38 |
| Amortization of discount on short-term investments, net | 278 |
| Gain on modification of lease liability | 1,005 |
| Stock-based compensation | 8,314 |
| Non-cash interest expense related to sale of future royalties | 2,823 |
| Non-cash revenue related to sale of future royalties | 4,521 |
| Accounts receivable | 8,803 |
| Unbilled receivable from government contracts | 30,573 |
| Prepaid expenses and other assets | 16,103 |
| Prepaid clinical services, long-term | -34,898 |
| Accounts payable | 14,639 |
| Deferred revenue-Government Contract | -65,332 |
| Deferred revenue-Collaboration Revenue | 14,976 |
| Accrued and other liabilities | 33,735 |
| Net cash provided by (used in) operating activities | 7,714 |
| Purchases of property and equipment | 145 |
| Proceeds from sale of property and equipment | 5 |
| Purchases of investments | 23,228 |
| Proceeds from maturities of investments | 40,000 |
| Net cash provided by (used in) investing activities | 16,632 |
| Net proceeds from issuance of common stock-Ra Capital Healthcare Fund2025 | 4,201 |
| Net proceeds from issuance of common stock-June2024Offering | 0 |
| Net proceeds from issuance of common stock-Atthemarket Facility | 53 |
| Net proceeds from issuance of common stock-RACapital Healthcare Fund2024 | 0 |
| Shares acquired to settle employee tax withholding liabilities | 199 |
| Proceeds from issuance of common stock upon exercise of stock options | 3 |
| Proceeds from issuance of common stock under the employee stock purchase plan | 0 |
| Proceeds from issuance of treasury stock under the employee stock purchase plan | 181 |
| Net cash provided by financing activities | 4,239 |
| Net increase (decrease) in cash and cash equivalents | 28,585 |
| Cash and cash equivalents at beginning of the period | 25,229 |
| Cash and cash equivalents at end of the period | 53,814 |
Vaxart, Inc. (VXRT)
Vaxart, Inc. (VXRT)